8. bibliography - shodhgangashodhganga.inflibnet.ac.in/bitstream/10603/25882/14/part... · 2018. 7....

Ph.D Thesis Estimation of New Anticancer…(Bibliography)

278

8. BIBLIOGRAPHY

Alan, D.B., Anne, M.E., Terry, M.H., Deborah, L.J., Andrew, M.M., Gordon, G.W.,

2002. Pyrrolidine-5,5-trans-lactams as Novel Mechanism-BasedInhibitors of

Human Cytomegalovirus Protease. Part 3:Potency and Plasma Stability

Bioorganic & Medicinal Chemistry Letters 12: 1719–1722.

Andrew, T., Turrisi, III., 1997. Combined Modality Therapy for Lung Cancer: Principles

to Practice. Oncologist (2): 192-195.

Ansede, J.H., Thakker, D.R., 2004. High –throughput screening for stability and

inhibitory activity of compound towards cytochrome P450- mediated

metabolism . J Pharm Sci 93(2): 293.

Anuj, K., Sangram, K.S., Kumud, P., Prithi, P.S.K., Ajit, S., Naveen P., 2011. Review on

solubility enhancement techniques for hydrophobic drugs, International journal

of comprehensive pharmacy 3(03).

Arutsson, P., Palm, K., Luthaman, K., 1996. Caco-2 monolayers in experimental and

theoretical prediction of drug transport. Adv Drug Del Rev 22: 67-84.

Aungst B. J., 1993. Novel formulation strategies for improving oral bioavailability of

drug with poor membrane permeation or presystemic metabolism. J Pharm Sci

82: 979–987.

Austel, V., 1989. The medicinal chemist's approach, in Modern Drug Research, Paths to

Better and Safer Drugs. Martin, Y.C., Kutter, E., Austel, V., Eds, Marcel

Dekker, Inc., New York, 243-307.

Avdeef, A., 2001. Physicochemical profiling (solubility, permeability and charge state.

Curr Topics Med Chem 1: 277-351.

Avery, M.J., 2003. Quantitative characterization of differential ion suppression on liquid

chromatography/atmospheric pressure ionization mass spectrometric

bioanalytical methods. Rapid Commun Mass Spectrom 17:197- 201.

Bache, M., Zschornak, P.M., Passin, S., Ke, J., Wichmann, H., Kappler, M., Paschke,

R., Kaluđerović, G.N., Kommera, H., Taubert, H., Vordermark, D., 2011.

Increased betulinic acid induced cytotoxicity and radiosensitivity in glioma

cells under hypoxic conditions, Radiation Oncology 6:111.

Bagnati, R., Fanelli, R., 1991. Determination of 19-nortestosterone, testosterone and

trenbolone by gas chromatography-negative-ion mass spectrometry after


279

formation of the pentafluorobenzylcarboxymethoxime-trimethylsilyl

derivatives. J Chromatogr 547: 325-334.

Baker, H.J., Lindsey, J.R., Weisbroth, S.H., 1979. The laboratory Rat, Vol. 1, Biology

and Diseases. Academic Press, New York, 87.

Balani, S.K., Miwa, G.T., Gan, L.S., Wu, J.T., Lee, F.W., 2005. Strategy of utilizing in

vitro and in vivo ADME tools for lead optimization and drug candidate

selection. Curr Top Med Chem 5(11): 1033-8.

Balimane, P.V., Chong, S., 2005. DDT 10(5): 335-343.

Baran, C.Z., Staricza, K.A., Sundberg, K., Sundberg, R., Wallin, A., Jansson, L., Garberg,

P., 2006. Introduction to in vitro estimation of metabolic stability and drug

intraction of new chemical entities in drug discovery and development.

Pharmacol Rep 58(4): 453.

Belanger, B., Couture, J., Caron, S., Bodou, P., Fiet, J., Belanger, A., 1990. Production

and secretion ofC-19 steroids by rat and guinea pig adrenals. Steroids 55(8):

360-365.

Benet, L.Z., 1978. Effect of route of administration and tissue distribution on drug action.

J Pharmacokinet Biopharm 6: 559-585.

Benet, L.Z., Mitchell, J.R., Sheiner, L.B. 1990. Pharmacokinetics : The dynamics of drug

absorption, distribution and elimination. In: The Pharmacological Basis of

Therapeutics, A Goodman Gilman, T.W., Rall, A.S., Nies, and P., Taylor, (eds).

Pergamon Press, Oxford, 1-32.

Benet, L.Z., Sheiner, L.B., 1985. Pharmacokinetics: The dynamics of drug absorption

distribution andelimination. In: The Pharmacological Basis of Therapeutics,

A.G., Gilman, L.S., Goodman, T.W., Ball, F., Mirac, (eds). Macmillan, New

York, 3-34.

Berger, M.R., 1999. Autochthonous tumour models in rats: Is there a relevance for

anticancer drug development. In: Fiebig HH, Burger AM, editors. Relevance of

Tumour Models for Anticancer Drug Development. Contrib Oncol 54: 15–27.

Berk, P.D., Potter, B.J., Stremmel, W., 1987. Role of plasma membrane ligand binding

proteins in the hepatocellular uptake of albumin bound anions. Hepatology 7:

165-176.

http://www.ncbi.nlm.nih.gov/pubmed?term=Balani%20SK%5BAuthor%5D&cauthor=true&cauthor_uid=16181128http://www.ncbi.nlm.nih.gov/pubmed?term=Miwa%20GT%5BAuthor%5D&cauthor=true&cauthor_uid=16181128http://www.ncbi.nlm.nih.gov/pubmed?term=Gan%20LS%5BAuthor%5D&cauthor=true&cauthor_uid=16181128http://www.ncbi.nlm.nih.gov/pubmed?term=Wu%20JT%5BAuthor%5D&cauthor=true&cauthor_uid=16181128http://www.ncbi.nlm.nih.gov/pubmed?term=Lee%20FW%5BAuthor%5D&cauthor=true&cauthor_uid=16181128http://www.ncbi.nlm.nih.gov/pubmed/16181128


280

Berman, J., Halm, K., Adkison, K., Shaffer, J., 1997. Simultaneous pharmacokinetic

screening of a mixture of compounds in dog using API/LC/MS/MS for

increased throughput. J Med Chem 40: 827-829.

Bertz, R.J., granneman, G.R., 1997. Use of in vitro and in vivo data to estimate the

likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:

210-258.

Bibby, M.C., 1999. Transplantable tumours in mice—the way forward. In: Burger AM,

editor. Relevance of tumour models for anticancer drug development. Contrib

Oncol 54: 1–13.

Bibby, M.C., 2004. Orthotopic models of cancer for preclinical drug evaluation:

advantages and disadvantages. Eur J Cancer 40: 852–7.

Bickel, M.H., 1975. Binding of chlorpromazine and imipramine to red cells, albumin,

Lipoproteins and other blood components. J Phrm Pharmacol 27: 733.

Bjorge, S., Halelehle, K.L., Homan, R., Rose, S.E., Turluck, D.A., Wright, D.S., 1991.

Evidence for glucuronide conjugation of p-nitrophenol in the CaCO-2 cell

model. Pharm Res 8: 1441-1443.

Bohets, H., Annaert, P., Mannens, G., Van, B.L., Anciaux, K., Verboven, P.,

Meuldermans, W., Lavrijsen, K., 2001. Strategies for absorption screening in

drug discovery and development. Curr Top Med Chem 1(5): 367.

Boik, J., 2001a. Natural compounds in cancer therapy. 1st Ed. Oregon Medical Press,

LLC, USA, 1-2.

Boobis, A., Gundert-Remy, U., Kremers, P., Macheras, P., Pelkonen, O., 2002. In silico

prediction of ADME and pharmacokinetics. Report of an expert meeting

organised by COST B15. Eur J Pharm Sci 17(4-5): 183-93.

Boyle, P., Levin, B., 2008. ―World Cancer Report 2008‖ IARC Nonserial Publication

(2008)

Bressolle, F., Bromet, P.M., Audran, M., 1996. Validation of liquid chromatographic and

gas chromatographic methods. Applications to pharmacokinetics. J Chromatogr

B 686(1): 3-10.

http://www.ncbi.nlm.nih.gov/pubmed?term=Boobis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=12453607http://www.ncbi.nlm.nih.gov/pubmed?term=Gundert-Remy%20U%5BAuthor%5D&cauthor=true&cauthor_uid=12453607http://www.ncbi.nlm.nih.gov/pubmed?term=Kremers%20P%5BAuthor%5D&cauthor=true&cauthor_uid=12453607http://www.ncbi.nlm.nih.gov/pubmed?term=Macheras%20P%5BAuthor%5D&cauthor=true&cauthor_uid=12453607http://www.ncbi.nlm.nih.gov/pubmed?term=Pelkonen%20O%5BAuthor%5D&cauthor=true&cauthor_uid=12453607http://www.ncbi.nlm.nih.gov/pubmed/12453607


281

Brodie. B.B., 1964. Physicochemical factors in drug absorption. In: Absorption and

Distribution of Drugs, TB Binns (ed). Williams and Wilkin, Baltimore,

Maryland, 16-48.

Bullock, P., Larsen, D., Press, R., Wehrman, T., Martin, D.E., 2008. The absorption,

distribution, metabolism and elimination of bevirimat in rats. Biopharm Drug

Dispos 29(7): 396-405.

Burger, A.M., 1999. Relevance of tumour models for anticancer drug development.

Contrib Oncol 54: 1–13.

Burton, P.S., Conradi, R.A., Gi, N.F.H., Hilgers, A.R., Borchardt, R.T., 1996. How

structural features influence the biomembrane permeability of peptides. J Pharm

Sci 85: 1336-1340.

Buters, J.T., Korzekwa, K.R., Kunze, K.L., Omata, Y., Hardwick, J.P., Gonzalez, F.J.,

1994. cDNA-directed expression of human cytochrome P450 CYP3A4 using

baculovirus. Drug Metab Dispos 22(5): 688-92.

Caldwell, G.W., Ritchie, D.M., Masucci, J.A., Hageman, W., Yan, Z., 2001. The new

pre-preclinical paradigm: compound optimization in early and late phase drug

discovery. Curr Top Med Chem (5): 353-66.

Caldwell, J., 1988. Xenobiotic metabolism—An introduction. In: Intermediary

Xenobiotic Metabolism, DH Hutson, J Caldwell, and GA Paulson (eds). Taylor

& Francis, London, 3-12.

Camenisch G., Alsenz, J., van de Waterbeemd, H., Folkers, G., 1998. Estimation of

permeability by diffusion through Caco-2 cell monolayers using the drugs´

liphophilicity and molecular weight. Eur J Pharm Sci 6: 313-319.

Campling, B., Pym, J., Baker, H., 1991. Chemosensitivity testing of small cell lung

cancer using the MTT assay. Br J Cancer 63: 75–83

Carmichael, J., DeGraff, W.G., Gazdar, A.F., Minna, J.D., Mitchell, J.B., 1987.

―Evaluation of a tetrazolium-based semiautomated colorimetric assay:

assessment of chemosensitivity testing‖. Cancer Res 47: 936-942.

Carmichael, J.W.G., DeGraff, A.F., Gazdar, J.D., Minna J.B.M. 1987. Evaluation of a

tetrazolium-based semiautomated colorimetric assay: assessment of

radiosensitivity. Cancer Res 47: 943-946.

Causon, R., 1997. Validation of chromatographic methods in biomedical analysis.

http://www.ncbi.nlm.nih.gov/pubmed?term=Caldwell%20GW%5BAuthor%5D&cauthor=true&cauthor_uid=11899102http://www.ncbi.nlm.nih.gov/pubmed?term=Ritchie%20DM%5BAuthor%5D&cauthor=true&cauthor_uid=11899102http://www.ncbi.nlm.nih.gov/pubmed?term=Masucci%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=11899102http://www.ncbi.nlm.nih.gov/pubmed?term=Hageman%20W%5BAuthor%5D&cauthor=true&cauthor_uid=11899102http://www.ncbi.nlm.nih.gov/pubmed?term=Yan%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=11899102http://www.ncbi.nlm.nih.gov/pubmed/11899102


282

Viewpoint and discussion. J Chromatogr B 689: 175-180.

Cayen, M.N., 1995. Considerations in the design of toxicokinetic programs. Tox Path 23:

148-157.

CDER Drug Development and Drug Interactions website.

http://www.fda.gov/cder/drug/drugInteractions/default.htm

Charles, G.S., 1992. The process of new drug delivery and development. CRC Press, Inc.

Boca Raton, Florida, USA.

Chatterjee, P., Kouzi, S. A., Pezzuto, J. M., Hamann, M. T., 2000. Biotransformation of

the antimelanoma agent betulinic acid by Bacillus megaterium ATCC 13368,

Appl Environ Microbiol 66: 3850-3855.

Chatterjee, P., Pezzuto, J.M., Kouzi, S.A., 1999. Glucosidation of betulinic acid by

Cunninghamella species. J Nat Prod 62: 761–763.

Chaturvedi, P.R., decker, C.J., Odinecs, A., 2001. Prediction of pharmacokinetics

properties using experimental approaches during early drug discovery. Curr

Opin Chem Biol 5(4): 425.

Cheeke, P.R., Digestive Physiology in Rabbit Feeding and Nutrition. Orlando, FL:

Academic Press. 20: 1987.

Chen, J., Korfmacher, W.A., Hsieh, Y., 2005. Chiral liquid chromatography-tendem

mass spectrometric methods for stereoisomeric pharmaceutical determinations.

J Chromatogr B 820: 1-8.

Chen, W.D., Liang. Y., Xie, L., Lu, T., Liu, X.D., Wang, G.J., 2007. Biol Pharm Bull 30:

1–5. Chen, W.D., Liang, Y., Li, H., Xiong, Y., Liu, X.D., Wang, G.J., Xie, L.,

2006. J Pharm Biomed Anal 41: 256–260.

Cheng, X., Shin, Y.G., Levine, B.S., Smith, A.C., Tomaszewski, J.E., Van-Breemen,

R.B., 2003. Quantitative analysis of betulinic acid in mouse, rat and dog plasma

using electrospray liquid chromatography/mass spectrometry. Rapid Commun

Mass Spectrom 17(18): 2089-92.

Chintharlapalli, S., Papineni, S., Lei, P., Pathi, S., Safe, S., 2011. Betulinic Acid Inhibits

Colon Cancer Cell And Tumor Growth And Induces Proteasomedependent

And - Independent Downregulation Of Specificity Proteins (Sp)

http://www.fda.gov/cder/drug/drugInteractions/default.htmhttp://www.ncbi.nlm.nih.gov/pubmed?term=Cheng%20X%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=Shin%20YG%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=Levine%20BS%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=Smith%20AC%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=Tomaszewski%20JE%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=van%20Breemen%20RB%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=van%20Breemen%20RB%5BAuthor%5D&cauthor=true&cauthor_uid=12955738http://www.ncbi.nlm.nih.gov/pubmed?term=Cheng%202003%20Quantitative%20analysis%20of%20betulinic%20acid%20in%20mousehttp://www.ncbi.nlm.nih.gov/pubmed?term=Cheng%202003%20Quantitative%20analysis%20of%20betulinic%20acid%20in%20mouse


283

Transcription Factors, BMC Cancer 11: 371.

Chu, L., Nomeir, A.A., 2006. Utility of mass spectrometry for in vitro ADME assays.

Curr Drug Metab 7(5): 467.

Cichewicz, R.H., Kouzi, S.A., 2004. Chemistry, biology activity, and chemotherapeutic

potential of betulinic acid for the prevention and treatment of cancer and HIV

infection. Med Res Rev 24: 90-114.

Clark, A.M., Hufford, C.D., 1991. Use of microorganisms for the study of drug

metabolism: An update. Med Res Rev 11: 437–501.

Clarke, N.J., Rindgen, D., Korfmacher, W.A., Cox, K.A., 2001. Systematic LC-MS

metabolite identification in drug discovery. Anal Chern 73: 430.

Cole, S.P., 1986. Rapid chemosensitivity testing of human lung tumor cells using the

MTT assay. Cancer Chemother Pharmacol 17(3): 259–263.

Copechot, C., Young, J., Calve, M., Wehrey, C., Veltz, I.N., Touyer, G., Mouren, M.,

Prasad, V.V.K., Banner, C., Sjovali, J., Baulieu, E.E., Robel P., 1993.

Neurosteroid3α: -hydroxy-5a-pregnan-20-one and its precursors in the brain,

plasma, and steroidogenic glands of male and female rats. Endocrinology 133:

1003-1009.

Covey, T.R., Lee, E.D., Henion, J.D., 1986. High-speed liquid chromatography/tandem

mass spectrometry for the determination of drugs in biological samples. Anal

Chern 58: 2453-2460.

Cragg, G.M., Newman, D.J., 2005. Plants as a source of anti-cancer agents. J

Ethnopharmacol 100(1-2): 72-79.

Crespi, C.L., Gonzalez, F.J., Steimel, D.T., Turner, T.R., Gelboin, H.V., Penman, B.W.,

Langenbach, R., 1991. A metabolically competent human cell line expressing

five cDNAs encoding procarcinogen-activating enzymes: aplication to

mutagenicity testing. Chem Res Toxicol 4: 566-572.

Croley, T.R., Hughes, R.J., Koenig, B.G., Metcalf, C.D., March, R.E., 2000. Mass

spectrometry applied to the analysis of estrogens in the environment. Rapid

Commun Mass Spectrom 14: 1087-1093.

Dadgar, D., Burnett, P.E., 1995. Issues in evaluation of bioanalyticaJ method selectivity

and drug stability. Pharm Biomed Anal 14: 23-31.

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Cragg%20GM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlushttp://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Newman%20DJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlusjavascript:AL_get(this,%20'jour',%20'J%20Ethnopharmacol.');javascript:AL_get(this,%20'jour',%20'J%20Ethnopharmacol.');


284

Dadgar, D., Burnett, P.E., Choc, M.G., Gallicano, K., Hooper, J.W., 1995. Application

issues in bioanalytical method validation, sample analysis and data reporting. J

Pharm Biomed Anal 13(2): 89-97.

Darvas, F., Keseru, G., Papp, A., Dorman, G., Urge, L., Krajcsi, P., 2002. In Silico and

Ex silico ADME approaches for drug discovery. Curr Top Med Chem 2(12):

1287-304.

Dass, C., 1999. Recent developments and applications of high-performance liquid

chromatography-electro spray ionization mass spectrometry. Curr Org Chern 3:

193-200

Davies, B., Morris, T., 1993. Physiological parameters in laboratory animals and

humans. Pharm Res. 10: 1093.

Decker, S., Hollingshead, M., Bonomi, C.A., Carter, J.P., Sausville, E.A., 2004. The

hollow fibre model in cancer drug screening; the NCI experience. Eur J Cancer

40: 821–6.

Delie, F., Rubas, W., 1997. A human colonic cell sharing similarities with enterocytes as

a model to examine oral absorption advantages and limitations of the Caco-2

model. Crit. Rev. Ther Drug Carrier Syst 14: 221-286.

Deng, Y., Synder, J.K., 2002. Preparation of a 24-nor-1,4-dien-3-one triterpene

derivatives from betulin: a new route to 24-nortriterpene analogues. J Organ

Chem 67: 2864-2873.

Deng, Y.X., Lu, T., Xie, L., Liu, X.D., 2005. Biomed Chromatogr 20: 1098–1002.

Dokoumetzidis, A., Kalantzi, L., Fotaki, N., 2007. predictive models for oral drug

absorption : from in silico methods to integrated dynamical models. Expert Opin

Drug Metab Toxicol 3(4): 491.

Donehower, L.A., Harvey, M., Slagle, B.L., 1992. Mice deficient for p53 are

developmentally normal but susceptible to spontaneous tumours. Nature 356:

215–21.

Draft guidance for industry: drug interaction studies—study design, data analysis, and

implications for dosing and labeling.

http://www.fda.gov/cder/guidance/6695dft.pdf.

http://www.ncbi.nlm.nih.gov/pubmed?term=Darvas%20F%5BAuthor%5D&cauthor=true&cauthor_uid=12470281http://www.ncbi.nlm.nih.gov/pubmed?term=Keseru%20G%5BAuthor%5D&cauthor=true&cauthor_uid=12470281http://www.ncbi.nlm.nih.gov/pubmed?term=Papp%20A%5BAuthor%5D&cauthor=true&cauthor_uid=12470281http://www.ncbi.nlm.nih.gov/pubmed?term=Dorm%C3%A1n%20G%5BAuthor%5D&cauthor=true&cauthor_uid=12470281http://www.ncbi.nlm.nih.gov/pubmed?term=Urge%20L%5BAuthor%5D&cauthor=true&cauthor_uid=12470281http://www.ncbi.nlm.nih.gov/pubmed?term=Krajcsi%20P%5BAuthor%5D&cauthor=true&cauthor_uid=12470281http://www.ncbi.nlm.nih.gov/pubmed/12470281http://www.fda.gov/cder/guidance/6695dft.pdf


285

Durrence, C.W., DiPiro, J.T., May, J.R., 1985. Potential drug interactions in surgical

ptients. Am J Hosp Pharm 42: 1553-1555.

Ekins, S., Ring, B.J., Grace, J., McRobie-Belle, D.J., Wrighton, S.A., 2000. Present and

future in vitro approaches for drug metabolism . J pharmacol Toxicol Methods

44(1): 313.

Ekins, S., Waller, C.L., Swaan, P.W., Cruciani, G., Wrighton, S.A., Wikel, J.H., 2000.

Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol

Methods 44(1): 251-72.

El Hilali, N., Rubio, N., Martinez-Villacampa, M., Blanco, J., 2002. Combined

noninvasive imaging and luminometric quantification of luciferase-labeled

human prostate tumors and metastases. Lab Invest 82: 1563–71.

Evans, G.H., Shand, D.G., 1973. Disposition of propanolol, Drug accumulation and

steady state concentrations during chronic oral administration in man. Clin

Pharmacol Therap 14: 487.

Evers, M., Poujade, C., Soler, F., Ribeill, Y., James, C., Lelievre, Y., Gueguen, J.C.,

Residorf, D., Morize, I., Pauwels, R., Clercq, D.E., Henin, Y., Bousseau, A.,

Mayaux, F.J., Pecq, B.J., Dereu, N., 1996. Betulinic Acid derivatives: A new

class of human immunodeficiency virus type I Specific inhibitors with a new

mode of action. J Medicin Chem 39: 1056-1068.

FDA., 1999. Guidance for Industry. In vivo drug metabolism/drug interaction studies-

study design, data analysis, and recommendations for dosing and labeling.

www.fda.gov/cder/guidance

Fidler, I.J., 1986. Rationale and methods for the use of nude mice to study the biology

and therapy of human cancer metastasis. Cancer Metastasis Rev 5: 29–49.

Fidler, I.J., Naito, S., Pathak, S., 1990. Orthotopic implantation is essential for the

selection, growth and metastasis of human renal cell cancer in nude mice

[corrected]. Cancer Metastasis Rev 9: 149–65.

Fiebig, H. H., Schmid, J. R., Bieser, W., Henss, H., and Löhr, G. W., 1987. Colony assay

with human tumor xenografts, murine tumors and human bone marrow.

Potential for anticancer drug development. Eur J Cancer Clin Oncol 23: 937–

948.

http://www.ncbi.nlm.nih.gov/pubmed?term=Ekins%20S%5BAuthor%5D&cauthor=true&cauthor_uid=11274894http://www.ncbi.nlm.nih.gov/pubmed?term=Waller%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=11274894http://www.ncbi.nlm.nih.gov/pubmed?term=Swaan%20PW%5BAuthor%5D&cauthor=true&cauthor_uid=11274894http://www.ncbi.nlm.nih.gov/pubmed?term=Cruciani%20G%5BAuthor%5D&cauthor=true&cauthor_uid=11274894http://www.ncbi.nlm.nih.gov/pubmed?term=Wrighton%20SA%5BAuthor%5D&cauthor=true&cauthor_uid=11274894http://www.ncbi.nlm.nih.gov/pubmed?term=Wikel%20JH%5BAuthor%5D&cauthor=true&cauthor_uid=11274894http://www.ncbi.nlm.nih.gov/pubmed/11274894http://www.ncbi.nlm.nih.gov/pubmed/11274894http://www.fda.gov/cder/guidance


286

Fiebig, H.H., 2004. Clonogenic assay with established human tumour xenografts:

correlation of in vitro to in vivo activity as a basis for anticancer drug discovery.

Eur J Cancer 40: 802–820.

Fluda, S., Scaffidi, C., Susin, S.A., Krammer, P.H., Kroemer, G., Peter, M.E., Dabtain,

K.M., 1998. Activation of mitochondria and release of mitochondrial

apoptogenic factors by betulinic acid. J Biol Chem 273(51): 33942-33948.

Fraga, M., 1990. Effect of type of fibre on the rate of passage and on the contribution of

soft feces to nutrient intake of finishing rabbits. Journal of Animal Science 69:

1566.

Freitas, L.G., G'otz, C.W., Ruff, M., Singer, H.P., M''uller, S.R., 2004. Quantification of

the new triketone herbicides, sulcotrione and mesotrione, and other important

herbicides and metabolites, at the ng/l level in surface waters using liquid

chromatographytandem mass spectrometry. J Chromatogr A 1028: 277-282.

Frick, L.W., Adkision, K.K., Knecht, K.J.W., Woollard, P., Higton. D.M., 1998. Cassette

dosing: rapid estimation of in vivo pharmacokinetics. Med Chem Res 8: 472-

477.

Frick, L.W., Adkision, K.K., Knecht, K.J.W., Woollard, P., Higton, D.M., 1998a.

Cassette dosing: rapid in vivo assessment of pharmacokinetics. Pharmaceut Sci

Technol Today 1: 12-18.

Friedman, M.A., Woodcock, J., Lumpkin, M.M., Shuren, J.E., Hass, A.E., Thompson,

L.J., 1999. The safety of newly approved medicines: do recent market removals

mean there is a problem. JAMA 281(18): 1728-34.

Frimmer, M., 1987. What we have learned from phalloidin. Tox Lett 35: 169-182.

Frimmer, M., 1989. Uptake of foreign cyclopeptides by liver cells. In: Hepatic Transport

of Organic Substances, E., Petzinger, R.K.H., Kinne, H., Sies, (eds). Springer-

Verlag, Berlin, Heidelberg.

Frimmer, M., and Ziegler, K., 1988. The transport of bile acids in liver cells. Biochem

Biophys Acta 947: 75-99.

Fu, I., Woolf, E., Matuszewski, B., 1998. Effect of the sample matrix on the

determination of indinavir in human urine by HPLC with turbo ion spray

tandem mass spectrometric detection. J Pharmaceut Biomed Anal 18: 347-357.

http://www.ncbi.nlm.nih.gov/pubmed?term=Friedman%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Woodcock%20J%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Lumpkin%20MM%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Shuren%20JE%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Hass%20AE%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Thompson%20LJ%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Thompson%20LJ%5BAuthor%5D&cauthor=true&cauthor_uid=10328074http://www.ncbi.nlm.nih.gov/pubmed?term=Friedman%20MA%201999%20the%20safety%20of%20newly%20approved%20medicine


287

Fulda, S., Debatin, K.M., 2000. Betulinic acid induces apoptosis through a direct effect

on mitochondria in neuroectodermal tumors. Med Pediatr Oncol 35: 616–618.

Fulda, S., Debatin, K.M., 2005. Sensitization for anticancer drug-induced apoptosis by

betulinic Acid. Neoplasia 7: 162-170.

Fulda, S., Friesen, C., Los, M., Scaffidi, C., Mier, W., Benedict, M., Nunez, G.,

Krammer, P.H., Peter, M.E., Debatin, K.M., 1997. Betulinic acid triggers CD95

(APO-1/Fas)- and p53-independent apoptosis via activation of caspases in

neuroectodermal tumors. Cancer Res 57: 4956–4964.

Fulda, S., Jeremias, I., Steiner, H.H., Pietsch, T., Debatin, K.M., 1999. Betulinic acid: A

new cytotoxic agent against malignant brain-tumor cells. Int J Cancer 82: 435–

441.

Fulda, S., Scaffidi, C., Susin, S.A., Krammer, P.H., Kroemer, G., Peter, M.E., Debatin, K-

M., 1998. Activation of mitochondria and release of mitochondrial apoptogenic

factors by betulinic acid. J Biol Chem 273: 33942–33948.

Gabizon, G., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., 1994.

Prolonged circulation time and enhanced accumulation in malignant exudates of

doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res

54: 987-992.

Gabizon, G., Papahadjopoulos, D., 1988. Liposome formulation with pro-longed

circulation time in blood and enhanced uptake by tumors. Proc Nat Acad Sci 85:

6949-6953.

Galgon, T., Wohlrab, W., Drager, B., 2005. Betulinic acid induces apoptosis in skin

cancer cells and differentiation in normal human keratinocytes. Exp Dermatol

14: 736-743.

Gan, L.S.L., Thakker, D.R., 1997. Application of the Caco-2 model in the design and

development of orally active drugs: elucidation of biochemical and physical

barriers posed by the intestinal epithelium. Adv Drug Deliv Rev 23: 77-98.

Ganesan, M., Nanjundan, S., Rauthan, K.S., Eswaran, K., 2010. Rapid analysis of

labetalol in human plasma using liquid chromatography tandem mass

spectrometry, International Journal of Pharmaceutical Sciences and Research

1: 209-218.


288

Gastearena, I., Dios-Vieitez, M.C., Terraz, M.M., Domingo, S., Fos, D., 1995.

Determination of the alpha1-acid glycoprotein binding of azithromycin in vitro

by equilibrium dialysis. J Chemother 4(7): 26-8.

Gibaldi, M., Boyes, R.N., Feldman, S., 1971. Influence of the first pass effect on the

availability of drugs on oral administration. J Pharm Sci 60: l338.

Gibaldi, M., Perrier, D., 1982. Pharmacokinetics, Marcel Dekkar Inc.: New York, 369.

Gidenne, T., 1992. Effect of fibre level, particle SIze and adaptation period on

digestibility and rate of passage as measured at the ileum and in the faeces in

the adult rabbit. British Journal of Nutrition 67: 133.

Gilbert, J.D., Olah, T.V., Barrish, A., Greber, T.F., 1992. Determination ofL-654,066, a

new 5 alpha-reductase inhibitor in plasma by /liquid

chromatography/atmospheric pressure chemical ionization mass spectrometry.

Biol Mass Spectrorn 21: 341-346.

Gombar, V.K., Silver, I.S., Zhao, Z., 2003. Role of ADME characteristics in drug

discovery and their in silico evaluation : in silico screening of chemicals for

their metabolic stability. Curr Top Med Chem 3 (11): 1205-1225.

Gorelik, E., Ovejera, A., Shoemaker, R., 1987. Microencapsulated tumor assay: new

short-term assay for in vivo evaluation of the effects of anticancer drugs on

human tumor cell lines. Cancer Res 47: 5739–47.

Gregus, Z., Klaassen, C.D., 1986. Enterohepatic circulation of toxicants. In:

Gastrointestinal Toxicity, K., Rozman, and O., Hanninen, (eds). Elsevier,

Amsterdam, 57-188.

Guengerich, F.P., Macdonald, T.L., 1990. Mechanisms of cytochrome P-450 catalysis.

FASEB J 4: 2453-2459.

Guengerich, F.P., 1993. The 1992 Bernard B Brodie award lecture. Bioactivation and

detoxication of toxic and carcinogenic chemicals. Drug Metab Dispos 2: 1-5.

Guidance for Industry, 2001. Mass Spectrometry for Confirmation of the identity of

Animal Drug Residues, Draft Guidance. US Department of Health and Human

Services, Food and Drug Administration: Washington, DC.

Guidance for Industry: Bioanalytical Method Validation, 2001. U.S. Department of

Health and Human Services, Food and Drug Administration Centre for Drug

Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM).


289

Guo, B., Li, C., Deng, Z., Chen, S., Ji, Z., Zhang, J., Chen, M., Xu, F., 2005. A new

method for measurement of (-)-sophocarpine, a candidate therapeutic for viral

myocarditis, in plasma: application to a toxicokinetic study in beagle dogs. Rap

Commun Mass Spectromet 19: 2840-2848.

Guttendorf, R.J., Andress, L., Okonkwo, G., Lesch, M., Finkel, M., Schrier, D., Loewen,

G., 1992. Pharmacokinetic and pharmacodynamic assessment of a novel

antiinflammatory drug in early discovery. Pharm Res 9: S- 356.

Harris, P.A., Riegelman, S., 1969. Influence of the route of administration on the area

under the plasma-concentration-time curve. J Pharm Sci 58: 71.

Hartmann, C., Smeyers-Verbeke, J., Massart, D.L., McDowall, R.D., 1998. Validation of

bioanalytical chromatographic methods. J Pharm Biomed Anal 17:1 93-218.

Hasegawa, T., Saneyioshi, N., Kawaguchi, T., 1996. Intestinal absorption and first pass

metabolism of 2, 3,-dideoxynucleotides following oral administration in rats.

Bio Pharm Bull 19: 599.

Hastings, K.L., El-Hage, J., Jacobs, A., Leighton, J., Morse, D., Osterberg, R., 2003.

Toxicol Appl Pharmacol 190: 91–92.

Hata, K., Hori, K., Takahashi, S., 2002. Differentiation- and apoptosis-inducing activities

by pentacyclic triterpenes on a mouse melanoma cell line. J Nat Prod 65: 645–

648.

Hawksworth, G.M., 1994. Advantages and disadvantages of using human cells for

pharmacological and toxicological studies. Hum Exp Tox 13: 568-573.

Hayon, T., Dvilansky, A., Shpilberg, O., Nathan, I., 2003. Appraisal of the MTT-based

assay as a useful tool for predicting drug chemosensitivity in leukemia. Leuk

Lymphoma 44: 1957–1962.

Hedman, A., Angelin, B., Ardvisson, A., Beck, O., Dahlqvist, R., Nilsson, B., Olsson, M.,

Schenk-Gustafsson, K., 1991. Digoxin-verapamil interaction: Reduction of

biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 49: 256-

262.

Henion, J., Brewer, E., Rule, G., 1998. Sample preparation for LC/MS/MS: analyzing

biological and environmental samples. Anal Chern 70: 650-656.

Heykants, J., Meuldermans, W., 1994. Nonclinical Kinetics and Metabolism Studies in

Support of the Safety Assessment of Drugs. Drug Information Journal 28: 163-

172.


290

Hidalgo, I.J., 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a

model system for intestinal epithelial permeability. Gastroenterology 96: 736-

749.

Hladky, S.B., 1990. Pharmacokinetics. Manchester University Press, Manchester, New

York.

Hoener, B-A., 1994. Predicting the hepatic clearance of xenobiotics in humans from in

vitro data. Biopharm Drug Disp 15: 295-304.

Hoffman, R.M., 1997. Fertile seed and rich soil: The development of clinically relevant

models of human cancer by surgical orthotopic implantation of intact tissues. In:

Teicher B, editor. Anticancer drug development guide: preclinical screening,

clinical trials, and approval. Totowa, N.J., Humana Press, Inc. 127–44.

Hoffman, R.M., 1999. Visualisation of metastasis in orthotopic mouse models with green

fluorescent protein. In: Fiebig, H.H., Burger, A.M., editors. Relevance of

tumour models for anticancer drug development. Contrib Oncol. 54: 81–7.

Hollingshead, M.G., Alley, M.C., Camalier, R.F., 1995. In vivo cultivation of tumor cells

in hollow fibers. Life Sci 57:131–41.

Houston, J.B., 1994. Utility of in vitro drug metabolism data in predicting in vivo

metabolic clearance. Biochem Pharmacol 47: 1469-1479.

Huang, S.M., Strong, J.M., Zhang, L., Reynolds, K.S., Nallani, S., Temple, R., Abraham,

S., Al, H.S., Baweja, R.K., Burckart, G.J., Chung, S., Colangelo, P., Frucht, D.,

Green, M.D., Hepp, P., Karnaukhova, E., Ko, H.S., Lee, J.I., Marroum, P.J.,

Norden, J.M., Qiu, W., Rahman, A., Sobel, S., Stifano, T., Thummel, K., Wei,

X.X., Yasuda, S., Zheng, J.H., Zhao, H., Lesko, L.J., 2008. New era in drug

interaction evaluation: US food and drug administration update on CYP

enzymes, transporters, and the guidance process. J Clin Pharmacol 48(6): 662–

670.

Huang, S.M., Temple, R., Throckmorton, D.C., Lesko, L.J. 2007. Drug interaction

studies: study design, data analysis, and implications for dosing and labeling.

Clin Pharmacol Ther 81(2): 298–304.

Hubbard, W., Bickel, C., Scheimer, R.P., 1994. Simultaneous Quantitation of

Endogenous Levels of Cortisone and Cortisol in Human Nasal and

Bronchoalveolar Lavage Fluids and Plasma via Gas Chromatography-Negative

Ion Chemical Ionization Mass Spectrometry. Anal Biochem 221: 109-117.


291

Humphrey, M.J., 1989. Pharmacokinetic studies in the selection of new drugs: a case

history on dihydropyridine calcium channel blockers. in Xenobiotic Metabolism

and Disposition, eds Kato, R., Estahrook, R.W., Gayen M.N., (Taylor & Francis,

New York), 245–253.

Humphreys, W.G., Unger, S.E., 2006. Chem Res Toxicol 19: 1564–1569.

Hunter, J., Hirst, B.H., Simmons, N.L., 1993. Transepithelial secretion, cellular

accumulation and cytotoxicity of vinblastine in defined MDCK cell strains.

Biochim Biophys Acta 1179: 1-10.

Huss, W.J., Maddison, L.A., Greenberg, N.M., 2001. Autochthonous mouse models for

prostate cancer: past, present and future. Semin Cancer Biol 11: 245–60.

ICH Q2 (R1), 1995. Note for guidance on validation of analytical procedures

(CPMP/ICH/38/95)

Imre, S., Vlase, L., Muntean, D.L., 2008. Bioanalytical method validation, Revista

Romana de Medicina de Laborator 10: 13-21.

Indap, M.A., Ambaye, R.Y., 1991. Efficacy of 5-fluorouracil in combination with

methoxyphenyl maleamic acid in murine tumors. J Postgrad Med 37(4): 211-

215.

Inui, K-I., Yamamoto, M., Saito, H., 1992. Transepithelial transport of oral

cephalosporins by monolayers of intestinal epithelial cell line CaCO-2:

specific transport systems in apical and basolateral membranes. J Pharmacol

Exp Ther 261: 195-201.

Irvine, J.D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J.W., Selick, H.E., Grove,

J.R., 1999. MDCK (Madin-Darby canine kidney) cells: A tool for membrane

permeability screening. J Pharm Sci 88: 28-33.

Ishihara, M., Sakagami, H., Liu, W.K.K. 2005. Quantitative Structure-Cytotoxicity

Relationship Analysis of Betulinic Acid and its Derivatives by Semi-empirical

Molecular-orbital Method, Anticancer Research 25: 3951-3956

Issar, M., Singh, S.K., Mishra, B., Gupta, R.C., 2003. Pharmacokinetics, insitu

absorption and protein binding studies of new neuroleptic agent centbutindole

in rats. Eur J Pharm Sci 19: 105.

Jaggi, M., Mukherjee, R., 1995. Establishment of tumorogenic cell lines from biopsies of

human colon adenocarcinoma. J Appl Biomed 3: 27-35.

javascript:AL_get(this,%20'jour',%20'J%20Postgrad%20Med.');


292

Jang, G.R., Harris, R.Z., Lau, D.T., 2001. Pharmacokinetics and its role in smass

molecule drug discovery research. Med Res Rev 21(5): 382.

Jansen, P.L.M., Oude-Elferink, R.P.J., 1993. Defective hepatic anion secretion in mutant

TR- rats. In: Hepatic Transport and Bile Secretion: Physiology and

Pathophysiology, distribution and elimination of drugs with special ref erences

to the category of organic cations. J Pharmaco Biopharm 18: 35-70.

Jeong, H.J., Chai, H.B., Park, S.Y., Kim, D.S., 1999. Preparation of amino acid

conjugates of betulinic acid with activity against human melanoma. Bioorgan

Med Chem Lett 9: 1201-1204.

Jeong, T.S., Hwang, E.I., Lee, H.B., Lee, E.S., Kim, Y.K., Min, B.S., Bae, K.H., Bok,

S.H., Kim, S.U., 1999. Chitin synthase II inhibitory activity of ursolic acid,

isolated from Crataegus pinnatifida. Planta Med 65: 261–263.

Jerry, Z.Y., Weiqing, C., Ronald, T.B., 2002. In Vitro Stability and In Vivo

Pharmacokinetic Studies of a Model Opioid Peptide, H-Tyr-D-Ala-Gly-Phe-D-

Leu-OH (DADLE), and Its Cyclic Prodrug. Pharmacology 303: 840-848.

Jia, L., Blantz, R.C., 1998. Eur J Pharmacol 354: 33–41.

Jia, L., Coward, L.C., Kerstner-Wood, J., Gorman, G., Noker, P., Kitada, S., Pellecchia,

M.P., Reed, J.C., 2007. Cancer Chemother Pharmacol 60: 570–80.

Jia, L., Noker, P.E., Coward, L., Gorman, G., Protopopova, M., Tomaszewski, J.E., 2006.

Br J Pharmacol 147: 476–485.

Jia, L., Tomaszewski, J.E., Noker, P.E., Gorman, G.S., Glaze, E., Protopopova, M., 2005.

J Pharm Biomed Anal 37: 23–33.

Jia, L., Wong, H., Wang, Y., Garza, M., Weitman, S.D., 2003. J Pharm Sci 92: 161–172.

Jia, L., Young, X., Guo, W., 1999. J Pharm Sci 88: 981–986.

Jia, L., Yu, L., Linnik, D.M., Jack, R.M., 2001. J Pharm Pharmacol 53: 999–1005.

Jia. L., Schweikart, K., Tomaszewski, J., Reed, J., Ames, M., Page, J., Noker, P., Munn,

D., 2007. Food Chem Toxicol 68-73.

Jiunn, H., Lin, Anthony, Y. H. L., 1997. Role of Pharmacokinetics and Metabolism in

Drug Discovery and Development, Pharmacological Reviews 49: 4 403-449.

Kamalraj, R., Devdass, G., Rajalakshimi, V., Nithin, J., 2012. Bioanalytical method

development models and validation for drug and its metabolite by using

LCMS/MS: An review, Journal of Pharmacy Research 5: 377-380.

http://pharmrev.aspetjournals.org/search?author1=Jiunn+H.+Lin&sortspec=date&submit=Submithttp://pharmrev.aspetjournals.org/search?author1=Anthony+Y.+H.+Lu&sortspec=date&submit=Submit


293

Kamimoto, Y., Gatmaitan, Z., Hsu, J., Arias, I.M., 1989. The function of Gp 170

multidrug resistance gene product. in rat liver canalicular membrane vesicles. J

Biol Chem 264: 11693-11698.

Kansey, M., Fische, H., Kratzat, K., Senner, F., Wagner, B., Parrilla, I., 2001. High-

throughput artificial membrane permeability studies in early lead discovery and

development. Pharmacokinet. Optim Drug Res 11: 448-464.

Kansey, M., Senner, F., Gubernator, K., 1998. Physiochemical high throughput screening:

parallel artificial membrane permeation assay in the description of passive

absorption process. J Med Chem 41: 1007-1010.

Kariv, I., Rourick, R.A., Kassel, D.B., Chung, T.D., 2002. Improvement of "hit-to-lead"

optimization by integration of in vitro HTS experimental models for early

determination of pharmacokinetic properties. Comb Chem High Throughput

Screen 5(6):459-72.

Karlsson, M.O., Bredberg, U., 1989. Estimation of bioavailability on a single occasion

after semisimultaneous drug administration. Pharm Res 6: 817-821.

Kasperczyk, H., La, Ferla-Bruhl, K., Westhoff, M.A., Behrend, L., Zwacka, R.M.,

Debatin, K.M., 2005. Betulinic acid as new activator of NF-kappaB: molecular

mechanisms and implications for cancer therapy. Oncogene 24: 6945-6956.

Kassel, D.B., 2004. Applications of high-throughput ADME in drug discovery. Curr

Opin Chem Biol 8(3): 339-45.

Katya, T., Michel, B., Aloise, M., 2009. The Alzheimer's Drug Discovery Foundation.

ADDME – Avoiding Drug Development Mistakes Early: central nervous system

drug discovery perspective. BMC Neurology 9(Suppl 1): S1.

Kelland, L.R., 2004. Of mice and men: values and liabilities of the athymic nude mouse

model in anticancer drug development. Eur J Cancer 40: 827–36.

Kerbel, R.S., 2003. Human tumor xenografts as predictive preclinical models for

anticancer drug activity in humans: better than commonly perceived—but they

can be improved. Cancer Biol Ther 2: S134–9.

Kerns, E., Di, L., Petusky, S., Farris, M., Ley, R., Jupp, P., 2004 Combined application of

parallel artificial membrane permeability assay and Caco-2 permeability assays

in drug discovery. J Pharm Sci 93:1440–1453.

Khurana, M., Lala, J., Singh, M.M., Paliwal, J.K., Kamboj, V.P., Gupta, R.C., 2002.

http://www.ncbi.nlm.nih.gov/pubmed?term=Kariv%20I%5BAuthor%5D&cauthor=true&cauthor_uid=12470275http://www.ncbi.nlm.nih.gov/pubmed?term=Rourick%20RA%5BAuthor%5D&cauthor=true&cauthor_uid=12470275http://www.ncbi.nlm.nih.gov/pubmed?term=Kassel%20DB%5BAuthor%5D&cauthor=true&cauthor_uid=12470275http://www.ncbi.nlm.nih.gov/pubmed?term=Chung%20TD%5BAuthor%5D&cauthor=true&cauthor_uid=12470275http://www.ncbi.nlm.nih.gov/pubmed/12470275http://www.ncbi.nlm.nih.gov/pubmed/12470275http://www.ncbi.nlm.nih.gov/pubmed?term=Kassel%20DB%5BAuthor%5D&cauthor=true&cauthor_uid=15183334http://www.ncbi.nlm.nih.gov/pubmed/15183334http://www.ncbi.nlm.nih.gov/pubmed/15183334


294

Evaluation of interaction potential of certain concurrently administered drugs

with pharmacological and pharmacokinetic profile of centchroman in rats.

Contraception 66: 47.

Killion, J.J., Radinsky, R., Fidler, I.J., 1999. Orthotopic models are necessary to predict

therapy of transplantable tumors in mice. Cancer Metastasis Rev 17: 279–84.

Kim YJ, Koo MH and Kim DS. (2001) Development of C-20 modified betulinic acid

derivatives as antitumor agents. Bioorgan Med Chem Lett 11: 2405-2408.

Kim, D.S.H.L., Pezzuto, J.M., Pisha, E., 1998. Synthesis of betulinic acid derivatives with

activity against human melanoma. Bioorg Med Chem Lett 8: 1707–1712.

Kim, Y.J., Koo, M.H., Kim, D.S., 2001. Development of C-20 modified betulinic acid

derivatives as antitumor agents. Bioorgan Med Chem Lett 11: 2405-2408.

King, R., Bonfiglio, R., Fernandez-Metzler, C., Miller-Stein, C., Olah, T., 2000.

Mechanistic investigation of ionization suppression in electrospray ionization. J

American Societ Mass Spectromet 11: 942-950.

Kinoshita, K., Yang, Y., Koyama, K., Takahashi, K., Nishino, H., 1999. Inhibitory effect

of some triterpenes from cacti on 32P-incorporation into phospholipids of HeLa

cells promoted by 12-O-tetradecanoylphorbol-13- acetate. Phytomedicine 6: 7

3–77.

Kitamura, R., Matsuoka, K., Matsushima, E., Kawaguchi, Y., 2001. Improvement

precision of the liquid chromatographic-electro spray ionization tandem mass

spectrometric analysis of 3 '-C-ethynylcytidine in rat plasma. J Chromatogr B

754: 113-119.

Klassen, C.D., Watkins J.B., 1984. Mechanisms of bile formation, hepatic uptake and

biliary excretion. Pharmacol Rev 36: 313.

Kommera, H., Kaluđerović, G.N., Kalbitz, J., Paschke, R., 2011. Lupane

Triterpenoids— Betulin and Betulinic acid derivatives induce apoptosis in

tumor cells, Invest New Drugs 29: 266–272.

Kostiainen, R., Kotiaho, T., Kuuranne, T., Auriola, S., 2003. J Mass Spectrom 38: 357–

372.

Kouzi, S.A., Chatterjee, P., Pezzuto, J.M., Hamann, M.T., 2000. Microbial

transformations of the antimelanoma agent betulinic acid. J Nat Prod 63: 1653–

1657.


295

Kronbach, T., Mathys, D., Gut, J., Catin, T., Meyer, U.A., 1987. High-performance liquid

chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-

hydroxylase, and dextromethorphan O-demethylase in microsomes and purified

cytochrome P-450 isozymes of human liver. Anal Biochem 162(1): 24-32.

Krzyzanski, W., Jusko, W.J., 1998. Characterization of pharmacodynamic recession

slopes for direct and indirect response models. J Pharmacokin Biopharm 26:

409-436.

Kubinyi, H., 2003. Drug research: myths, hype and reality. Nat Rev Drug Discov 2: 665–

668.

Kumar, V., Rani, N., Aggarwal, P., Sanna, V.K., Singh, A.T., Jaggi, M., Joshi, N.,

Sharma, P.K., Irchhaiya, R., Burman, A.C., 2008. Synthesis and cytotoxic

activity of heterocyclic ring-substituted betulinic acid derivatives. Bioorgan

Med Chem Lett 18: 5058-5062. DOI:1016/j.bmcl.2008.08.003.

Kurz, J., Trunk, J., Weitz, B., 1977. Evaluation of methods to determine protein binding

of drugs, equilibrium dialysis, ultrafiltration, ultracentrifugaion and gel

filtration. Drug Res 27: 1373.

Kvasnica, M., Sarek, J., Klinotova, E., Dzubak, P., Hajduch, M., 2005. Synthesis of

phthalates of betulinic acid and betulin with cytotoxic activity. Bioorg Med

Chem 13: 3447-3454.

Kwon, H.J., Shim, J.S., Kim, J.H., Cho, H.Y., Yum, Y.N., Kim, S.H.,Yu, J., 2002.

Betulinic acid inhibits growth factor-induced in vitro angiogenesis via the

modulation of mitochondrial function in endothelial cells. Jpn J Cancer Res 93:

417–425.

Lacy, P.E., Hegre, O.D., Gerasimidi-Vazeou, A., Gentile, F.T., Dionne, K.E., 1991.

Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of

encapsulated islets. Science 254: 1785–4.

Lagana, A., Fago, G., Marino, A., Santarelli, D., 2001. Liquid chromatography tandem

mass spectrometry applied to the analysis of natural and synthetic steroids in

environmental waters. Anal Lett 34: 913-925.

Lahoz, A., Gombau, L., Donato, M.T., Castell, J.V., Gomez-Lechon, M.J., 2006. Invitro

ADME medium /high –throughput screening in drug preclinical development.

Mini Rev M ed Chem 6(9):1053.


296

Lan, P., Chen, W.N., Huang, Z.J., Sun, P.H., Chen, W.M., 2011. Understanding the

structure- activity relationship of betulinic acid derivatives as anti-HIV-1

agents by using 3D- QSAR and docking. J Mol Model 17: 1643–1659.

Lanza, R.P., Butler, D.H., Borland, K.M., 1991. Xenotransplantation of canine, bovine,

and porcine islets in diabetic rats without immunosuppression. Proc Natl Acad

Sci 88: 11100–4.

Lasser, K.E., Allen, P.D., Woolhandler, S.J., Himmelstein, D.U., Wolfe, S.M., Bor, D.H.,

2002. Timing of new black box warnings and withdrawals for prescription

medications. JAMA 287(17): 2215-20.

Lave, T., Dupin, S., Schmitt. C., Valles, B., Ubeaud, G., Chou, R.C., Jaeck, D., Coassolo,

P., 1997. The use of human hepatocytes to select compounds based on their

expected hepatic extraction ratios in humans. Pharm Res 14: 152-155.

Leahy, D.E., Lynch, J., Taylor, D.D., 1989. Mechanisms of absorption of small

molecules. in Novel Drug Delivery, eds Prescott, L.F., Nimmo, W.S., (John

Wiley & Sons, New York), 33–44.

Lee, J.S., Min, B.S., Bae, K.H., 1996. Cytotoxic constituents from the Forsythiae fructus

against L1210 and HL60 cells. Yakhak Hoeji 40: 462–467.

Lee, K.H., 1999. Anticancer Drug Design Based on Plant-Derived Natural Products. J

Biomed Sci 6(4): 236–250.

Lee, M.S., Kerns. E.H. 1999. LC/MS applications in drug development. Mass Spectrom

Rev 18: 187-279.

Lee, P.H., Cucurull-sanchez, L., Lu, J., Du, Y.J., 2007. Development of in silico models

for human liver microsomal stability. J Comput Aided Mol Des (epub ahead of

print).

Li, A.P., 2001. Screening for human ADME/Tox drug properties in drugdiscovery. Drug

Discovery Today (6)7: 357–366.

Li, A.P., 2004. In vitro approaches to evaluate ADMET drug properties .Curr Top Med

chem 4(7): 701.

Liang, H.R., Takagaki, T., Foltz, R.L., Bennett, P., 2005. Quantitative determination of

endogenous sorbitol and fructose in human nerve tissues by atmospheric-

http://www.ncbi.nlm.nih.gov/pubmed?term=Lasser%20KE%5BAuthor%5D&cauthor=true&cauthor_uid=11980521http://www.ncbi.nlm.nih.gov/pubmed?term=Allen%20PD%5BAuthor%5D&cauthor=true&cauthor_uid=11980521http://www.ncbi.nlm.nih.gov/pubmed?term=Woolhandler%20SJ%5BAuthor%5D&cauthor=true&cauthor_uid=11980521http://www.ncbi.nlm.nih.gov/pubmed?term=Himmelstein%20DU%5BAuthor%5D&cauthor=true&cauthor_uid=11980521http://www.ncbi.nlm.nih.gov/pubmed?term=Wolfe%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=11980521http://www.ncbi.nlm.nih.gov/pubmed?term=Bor%20DH%5BAuthor%5D&cauthor=true&cauthor_uid=11980521http://www.ncbi.nlm.nih.gov/pubmed?term=Lasser%20KE%202002%20timing%20of%20new%20black%20box


297

pressure chemical ionization liquid chromatography/tandem mass spectrometry.

Rap Commun Mass Spectromet 19: 2284-2294.

Libby, K., Marcy, E., 2007. Automation of Cell-Based and Noncell-Based Permeability

Assays, Journal of Laboratory Automation 12(2): 104-109.

Lin, J., Sahakian, D.C., de, M.S.M., Xu, J.J., Polzer, R.J., Winter, S.M., 2003. The role of

absorption, distribution, metabolism, excretion and toxicity in drug discovery.

Curr Top Med Chem 3(10): 1125-54.

Lin, J.H., 1994. Dose dependent pharmacokinetics: Experimental observations and

theoretical considerations. Biopharm Drug Dispos. 15: 1.

Lin, J.H., 1995. Species similarities and differences in pharmacokinetics . Drug Metab

Dispos 23(10): 1008.

Lin, J.H., 1996a. Bisphosphonates: a review of their pharmacokinetic properties. Bone

18: 75–85.

Lin, J.H., Lu, A.Y., 1997. Role of Pharmacokinetics and metabolism in Drug Discovery

and Development. Pharmacol Rev 49(4): 403-449.

Lin, J.H., Storey, D.E., Chen, I.W., Xu, X., 1996c. Improved oral absorption of L-

365,260, a poorly soluble drug. Biopharm. Drug Dispos 17: 1–16.

Lindner, W., Wainer, I.W., 1998. Requirements for initial assay validation and

publication in J Chromatography B 707: 1-2.

Lipinski, C., Lombardo, F., Dominy, B., Feeney, P., 2001. Experimental and

computational approaches to estimate solubility and permeability in drug

discovery and development settings. Adv Drug Deliv Rev 46: 3-26.

Lippi, A., Crieuoli, M., Guelfi, M., Santicioli, M., Maggi, C.I., 1998. Pharmacokinetics of

bicyclic peptide tachykinin NK2 receptor antagonist MEN 11420 (Nepadutant)

in rats. Drug Metab Dispos 26: 1077.

Litterst, C.L., Minnaugh, E.G., Reagon, R.L., Gram, T.E., 1975. Comparison of in vitro

drug metabolism by lung, liver and kidney of several common laboratory

species. Drug Metab Dispos 3: 259.

Liu, X.D., Xie, L., Gao, J.P., Lai, L.S., Liu, G.Q., 1997. Eur J Drug Metab

Pharmacokinet 22: 185–188.

http://www.ncbi.nlm.nih.gov/pubmed?term=Lin%20J%5BAuthor%5D&cauthor=true&cauthor_uid=12769713http://www.ncbi.nlm.nih.gov/pubmed?term=Sahakian%20DC%5BAuthor%5D&cauthor=true&cauthor_uid=12769713http://www.ncbi.nlm.nih.gov/pubmed?term=de%20Morais%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=12769713http://www.ncbi.nlm.nih.gov/pubmed?term=Xu%20JJ%5BAuthor%5D&cauthor=true&cauthor_uid=12769713http://www.ncbi.nlm.nih.gov/pubmed?term=Polzer%20RJ%5BAuthor%5D&cauthor=true&cauthor_uid=12769713http://www.ncbi.nlm.nih.gov/pubmed?term=Winter%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=12769713http://www.ncbi.nlm.nih.gov/pubmed/12769713


298

Liu, Y., 1999. Understanding the biological activity of amyloid proteins in vitro: from

inhibited cellular MTT reduction to altered cellular cholesterol homeostasis.

Prog Neuropsychopharmacol Biol Psychiatry 23: 377–395.

Lu, S., Guttendorf, R.J., Stewart, B.H., 1994. The mechanism of cefdinir transport in

CaCO-2 cells. Pharm Res 11: S-258.

Lu, T., Liang, Y., Song, J., Xie, L., Wang, G.J., Liu, X.D., 2006. J Pharm Biomed Anal

40: 1218–24.

Ma, J., Starck, S.R., Hecht, S.M., 1999. DNA polymerase b inhibitors from Tetracera

boiviniana. J Nat Prod 62: 1660–1663.

Ma, Y.C., Kim, H.Y., 1997. Determination of Steroids by Liquid Chromatography/Mass

Spectrometry. J Am Soc Mass Spectrorn 8: 1010-1020.

Macleod, K.F., Jacks, T., 1999. Insights into cancer from transgenic mouse models. J

Pathol 187: 43–60.

Makela, S.K., Eillis, G., 1988. Nonspecificity of a direct 17cx-hydroxyprogesterone

radioimmunoassay kit when used with samples from neonates. Clin Chern 34:

2070-2075.

Malgorzata, D.Z., Julita, K., Jolanta,, S., Teresa, W., Maciej, Z., Pawel, S., Marcin,

D., 2009. Esters of betulin and betulinic acid with amino acids have improved

water solubility and are selectively cytotoxic toward cancer cells, Bioorganic &

Medicinal Chemistry Letters 19: 4814–4817.

Mallet, C.R., Lu, Z., Mazzeo, J.R., 2004. A study of ion suppression effects in

electrospray ionization from mobile phase additives and solid-phase extracts.

Rap Commun Mass Spectromet 18: 49-58.

Martin, D.E., Blum, R., Doto, J., 2007. Multiple-dose pharmacokinetics and safety of

bevirimat, A novel inhibitor of HIV maturation, in healthy volunteers. Clin

Pharmacokinet 46(7): 589-98.

Martin, Y.C., Hansch, C., 1971. Influence of hydrophobic character on the relative rate of

oxidation of drugs by rat liver microsomes. J Med Chem 14: 777–779.

Masimirembwa, C.M., Breadburg, U., Andersson, T.B., 2003. Metabolic stability for drug

siacovery and development: pharmacokinetic and biochemical challenges. Clin

pharmacokinet 42(6): 515.


299

Matter, H., Baringhaus, K.H., Naumann, T., Klabunde, T., Pirard, B., 2001.

Computational approaches towards the rational design of drug-like compound

libraries. Comb Chem High Throughput Screen 4(6): 453-75.

Matuszewski, B., Constanzer, M.L., Chavez-Eng, C.M., 2003. Strategies for the

assessment of matrix effect in quantitative bioanalytical methods based on

HPLC-MS/MS. Analyt Chem 75: 3019-3030.

Meijer, D.K.F., 1989. Transport and metabolism in the hepatobiliary system. In:

Handbook of Physiology of the Gastrointestinal System, Vol. III, S.G., Schulz,

J.G., Forte, and B.B., Rauner, (eds). Oxford University Press, New York, 717-

758.

Meijer, D.K.F., Groothuis, G.M.M., 1991. Hepatic transport of drugs and proteins. In:

Oxford Textbook of Clinical Hepatology, Vol. 1, N., McIntyre, J., Benhama,

and H., Bircher, (eds). Oxford University Press, Oxford, 40-78.

Meijer, D.K.F., Mol, W.E.M., Muller, M., Kurz, G., 1990. Carrier mediated transport in

the hepatic distribution and elimination of drugs with special ref erences to the

category of organic cations. J Pharmaco Biopharm 18: 35-70.

Melzig, M.F., Bormann, H., 1998. Betulinic acid inhibits aminopeptidase N activity.

Planta Med 64: 655–657.

Mishra, G., Singh, M.K., Awasthi, A., Jaggi, M., Ahmad, F.J., 2011. LC-UV detection of

5-chloro-2,3-didehydroindolo[2’,3’:2,3] betulinic acid in rat plasma and its

application to a pharmacokinetic study. Chromatographia 73: 281-289. DOI

10.1007/s10337-010-1862-9.

Moser, A.R., Mattes, E.M., Dove, W.F., 1993. ApcMin, a mutation in the murine Apc

gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proc

Natl Acad Sci 90: 8977–81.

Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival:

application to proliferation and cytotoxicity assays. J Immunol Meth 65: 55–63.

Mummaneni, V., Dressman, B., 1994. Intestinal uptake of cimetidine and ranitidine in

rat. Pharm Res 11: 1599.

Nagaraja, N.V., Paliwal, J.K., Gupta, R.C., 1999. Choosing the calibration model in assay

validation. J Pharm Biomed Anal 20: 433-438.

http://www.ncbi.nlm.nih.gov/pubmed?term=Matter%20H%5BAuthor%5D&cauthor=true&cauthor_uid=11562252http://www.ncbi.nlm.nih.gov/pubmed?term=Baringhaus%20KH%5BAuthor%5D&cauthor=true&cauthor_uid=11562252http://www.ncbi.nlm.nih.gov/pubmed?term=Naumann%20T%5BAuthor%5D&cauthor=true&cauthor_uid=11562252http://www.ncbi.nlm.nih.gov/pubmed?term=Klabunde%20T%5BAuthor%5D&cauthor=true&cauthor_uid=11562252http://www.ncbi.nlm.nih.gov/pubmed?term=Pirard%20B%5BAuthor%5D&cauthor=true&cauthor_uid=11562252http://www.ncbi.nlm.nih.gov/pubmed/11562252


300

Nassar, A.E., Talaat, R.E., Kamal, A.M., 2006. The impact of recent innovation in the use

of liqid chromatography –mass spectrometry in support of drug metabolism

studies: are we the way there yet? Curr Opin Drug Discov Devel 9(1): 61.

Nebert, D.W., Nelson, D.R., Coon, M.J., Estabrook, R.W., Feyereisen, R., Fujii-

Kuriyama, Y., Gonzales, F.J., Guengerich, F.P., Gunsalas, I.C., Johnson, E.F.,

Loper, J., Sato, R., Waterman, M.R., Waxman, D.J., 1991. The P450

superfamily-Update on new sequences, gene mapping and recommended

nomenclature. DNA Cell Biol 10: 1-14.

Nebert, D.W., Nelson, D.R., Coon, M.J., Estabrook, R.W., Feyereisen, R., Fujii-

Kuriyama, Y., Gonzales, F.J., Guengerich, F.P., Gunsalas, I.C., Johnson, E.F.,

Loper, J.C., Sato, R., Waterman, MR., Waxman, D.J., 1991. Correction. DNA

Cell Biol 10: 397-398.

Newman, D.J., Cragg, G.M,, Snader, K.M., 2003. Natural products as sources of new

drugs over the period 1981-2002. J Natur Prod 66: 1022-1037.

Newman, D.J., Cragg, G.M., Snader, K.M., 2000. The influence of natural products upon

drug discovery. Natur Prod Rep 17(3): 215-234.

Nishida, T., Gatmaitan, Z., Che, M., Arias, I.M., 1991. Rat liver canalicular membrane

vesicles contain an ATP-dependent bile acid transport system. Proc Natl Acad

Sci 88: 6590-6594.

Nishida, T., Gatmaitan, Z., Roy-Chowdhury, J., Arias, I.M., 1992a. Two distinct

mechanisms for bilirubin glucuronide transport by rat bile canalicular membrane

vesicles. Demonstration of defective ATP-dependent transport in rats with

inherited conjugated hyperbilirubinaemia. J Clin Invest 90: 2130-2135.

Nishida, T., Hardenbrook, C., Gatmaitan, Z., Arias, I.M., 1992b. ATP-dependent organic

anion transport in normal and TR- rat liver canalicular membranes. Am J Physiol

262: 629-G635.

Noda, Y., Kaiya, T., Kohda, K., Kawazoe,Y., 1997. Enhanced cytotoxicity of some

triterpenes toward leukemia L1210 cells cultured in lowpHmedia: Possibly a

newmode of cell killing. Chem Pharm Bull 45: 1665–1670.

Nomikos, T.V., Pater, J.L., Seymour, L., 2003. Clinical predictive value of the in vitro

cell line, human xenograft, and mouse allograft preclinical cancer models.

Clinical Cancer Research 9(11): 4227–4239.


301

O’Reilly, R.A., Welling, P.J., Wagner, J.G., 1971. Pharmakinetics of warfarin following

intravenous administration in man. Throm Diath Haemorrh 25: 178.

Ohgiya, S., Komori, M., Fujitani, T., Miura, T., Shinriki, N., Kamataki, T., 1989. Cloning

of human cytochome P-450 cDNA and its expression in Saccharomyces

cerevisiae. Biochem Int 18: 429-438.

Oude Elferink, R.P.J., Ottenhof, R., Radominska, A., Hofmann, A., Kuipers, F., and

Jansen, P.L.M., 1991. Inhibition of glutathione-conjugate secretion from

isolated hepatocytes by dipolar bile acids and other organic anions. Biochem J

274: 281-286.

Paget, S., 1889. Secondary growths of cancer of breast. Lancet 1:571–3.

Palm, K., Stenberg, P., Luthman, K., Artursson, P., 1997. Polar molecular surface

properties predict the intestinal absorption of drugs in humans. Pharma Res 14:

568-571.

Panchugnula, R., Thomas. N.S., 2000. Biopharmaceutics and pharmacokinetics in drug

research. Int J Pharm 201: 131-150.

Park, J.G., Kramer, B.S., Steinberg, S.M., Carmichael, J., Collins, J.M., Minna, J.D.,

Gazdar, A.F., 1987. Chemosensitivity testing of human colorectal carcinoma

cell lines using a tetrazolium-based colorimetric assay. Cancer Res 47: 5875-

5879.

Pedraglio, S., Rozio, M.G., Misiano P., Reali, V., Dondio, G., Bigogno, C., 2007. New

perspectives in bioanalytical techniques for preclinical characterization of drug

candidate: UPLC-MS/MS in vitro metabolism and pharmacokinetic studies. J

Pharm Biomed Anal 44 (3): 665.

Perucca, E, Richens, A., 1979. Reduction of oral bioavailability of lignocaine by

induction of first pass metablism in epileptic patients. Br J Pharmacol 7: 21.

Peterson, J.K., Houghton, P.J., 2004. Integrating pharmacology and in vivo cancer models

in preclinical and clinical drug development. Eur J Cancer 40: 837–44.

Phillips, R.M., Bibby, M.C., Double, J.A., 1990. A critical appraisal of the predictive

value of in vitro chemosensitivity assays. J Natl Cancer Inst 82: 1457–68.

Piasky, K.M., 1980. Disease induced changes in the plasma binding of basic drugs. Clin

Pharmacoin 5: 246.

Pidgeon, C., Ong, S., 1995. Predicting drug-membrane interactions. Chemtech 38-48.


302

Pinto, M., 1983. Enterocyte-like differentiation and polarization of the human colon

carcinoma cell line Caco-2 in culture. Biol Cell 47: 323-330.

Piquette, M.M., Jamali, F., 1977. Pharmacokinetics and multiple peaking of acebutolol

enantiomers in rats. Biopharm Drug Dispos 18: 543.

Pisha, E., Chai, H., Lee, I.S., Chagwedera, T.E., Farnsworth, N.R., Cordell, A.C.,

Beecher, C.W.W., Fong, H.H.S., Kinghorn, A.D., Brown, D.M., Wani, M.C.,

Wall, M.E., Hieken, T.J., Das, Gupta, T.K., Pezzuto, J.M., 1995. Discovery of

betulinic acid as a selective inhibitor of human melanoma that functions by

induction of apoptosis. Nat Med 1: 1046–1051.

Plowman, J., 1997. Human tumour xenograft models in NCI drug development. In:

Teicher B, editor. Anticancer drug development guide: preclinical screening,

clinical trials, and approval: Humana Press Inc. 101–25.

Plowman, J., Camalier, R., Alley, M., Sausville, E., Schepartz, S., 1999. US-NCI testing

procedures. In: Fiebig HH, Burger AM, editors. Relevance of tumour models for

anticancer drug development. Contrib Oncol 54: 121–35.

Poggesi, L., 2004. Predicting human pharmacokinetics from preclinical data. Curr Opin

Drug Discov Devel 7(1): 100.

Pokrovskii, A.G., Shintyapina A.B., Pronkina N.V., Kozhevnikov V.S., Plyasunova

O.A., Shul’ts E.E., Tolstikov G.A., 2006. Activation of Apoptosis by

Derivatives of Betulinic Acid in Human Tumor Cells in vitro, Doklady

Biochemistry and Biophysics 407: 94–97.

Pond, S.M., Tozer, T.M., 1984. First pass elimination, basic concepts and clinical

consequences. Clin Pharmacokin 9: 1.

Powell, J.R., Vozeh. S., Hopewell, P., Costello, J., Sheiner, L.B., Reigelman, S., 1975.

Theophyline disposition in accurately ill hospitalized patients. Am Rev Respir

Dis 11: 229.

Prakash, C., Shaffer, C.L., Nedderman, A., 2007. Analytical strategies for identifying

drug metabolites. Mass spectrum Rev 26(3):340.

Prentis, R.A., Lis, Y., Walker, S.R., 1988. Pharmaceutical innovation by the seven UK-

owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 25(3):

387–396.

http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=PubMed&term=%20Prentis%2BRA%5bauth%5dhttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=PubMed&term=%20Lis%2BY%5bauth%5dhttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=PubMed&term=%20Walker%2BSR%5bauth%5d


303

Purdie, C.A., Harrison, D.J., Peter, A., 1994. Tumour incidence, spectrum and ploidy in

mice with a large deletion in the p53 gene. Oncogene 9: 603–9.

Qiu, L., Wang, Q., Di, W., Jiang, Q., Schefeller, E., Derby, S., Wanebo, H., Yan, B.,

Wan, Y., 2005. Transient activation of EGFR/AKT cell survival pathway and

expression of survivin contribute to reduced sensitivity of human melanoma

cells to betulinic acid. Int J Oncol 27(3): 823-30.

Qiuling, W.U., Jing, H.E., Jun, F.A.N.G., Mei, 2010. Antitumor Effect of Betulinic

Acid on Human Acute Leukemia K562 Cells in vitro, J Huazhong Univ Sci

Technol Med Sci 30(4): 453-457.

Reinoso, R.F., Farran, R., Moragon, T., Gracia-Soret, A., Martinez, L., 2001.

Pharamcokinetics of E-6087, anew anti-inflammatory agent, in rats and dogs.

Biopharm Drug Dispos 22: 231.

Rieber, M., Rieber, M.S., 1998. Induction of p53 without increase in p21WAF1 in

betulinic acid-mediated cell death is preferential for human metastatic

melanoma. DNA Cell Biol 17: 399–406.

Rieber, M., Rieber, M.S., 2006. Signalling responses linked to betulinic acid-induced

apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid

melanoma irrespective of p53 status. Int J Cancer 118: 1135-1143.

Rinaki, E., Valsami, G., Macheras, P., 2003. Quantitative Biopharmacuetics

Classification System; the central role of dose/solubility ratio. Pharm Res 20:

1917.

Roberts, S.A., 2001. High-throughput screening approaches for investigating drug

metabolism and pharmacokinetics. Xenobiotica 31(8-9): 557-89.

Roberts, S.A., 2003. Drug metabolism and pharmacokinetics in drug discovery. Curr

Opin Drug Discov Devel 6(1): 66-80.

Rodrigues, A.D., 1997. Preclinical drug metabolisim in the age of high–throughput

screening: an industrial perspective. Pharm Res 14: 1504- 1510.

Rose, J., Holbech, H., Lindholst, C., Nortum, U., Povlsen, A., Korsgaard, B., 2002.

Bjerrregaard CPo Vitellogenin induction by 17/3-estradiol and l Zo-

ethinylestradiol in male zebrafish (Danio rerio) Biochem Physio C 131: 531-

537.

http://www.ncbi.nlm.nih.gov/pubmed?term=Roberts%20SA%5BAuthor%5D&cauthor=true&cauthor_uid=11569526http://www.ncbi.nlm.nih.gov/pubmed/11569526http://www.ncbi.nlm.nih.gov/pubmed?term=Roberts%20SA%5BAuthor%5D&cauthor=true&cauthor_uid=12613278http://www.ncbi.nlm.nih.gov/pubmed/12613278http://www.ncbi.nlm.nih.gov/pubmed/12613278


304

Rothen-Rutishauser, B., Kraemer, S.D., Braun, A., Guenthert, M., Wunderli-Allenspach,

H., 1998. MDCK cell cultures as an epithelial in vitro model: cytoskeleton and

tight junctions as indicators for the definition of age-related stages by confocal

microscopy. Pharm Res 15: 964-971.

Rowland, M., 1972. Influence of route of administration on drug availability. J Pharm

Sci 1: 70.

Rubenstein, K., 2003. Advancein lead optimization accelerating drug discovery and

development. Report# 27, Cambridge healthcare Institute.

Rubinstein, L.V., Shoemaker, R.H., Paull, K.D., Simon, R.M., Tosini, S., Skehan, P.,

Scudiero, D., Monks, A., Boyd, M.R., 1990 Comparison of in vitro anticancer

drug screening datagenerated with a tetrazolium assay versus a protein assay

against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-

1118.

Rusmawati, W.M.W., Ahmad, F.B.H., Anuar, K., Hamdan, S., 2001. Solubility of

betulinic acid in the microemulsion system of methyl acetate/Tween 80:

BRIJ30/H2O. Oriental J Chem 16: 393–398.

Sabarinath, S., Madhusudanan, K.P., Gupta, R.C., 2005. Pharmacokinetics of the

diastereomers of arteether, a potent antimalarial drug, in rats. Biopharm Drug

Dispos. 26: 211.

Sakaguchi, E., 1990. Digesta retention and fibre digestion in brushtail possums, ringtail

pos sums and rabbits. Comparative Biochemistry and Physiology 96A: 351.

Salti, G.I., Kichina, J.V., Das, Gupta, T.K., Uddin, S., Bratescu, L., Pezzuto, J.M., Mehta,

R.G., Constantinou, A.I., 2001. Betulinic acid reduces ultraviolet-C-induced

DNA breakage in congenital melanocyte naeval cells: Evidence for a potential

role as a chemopreventive agent. Melanoma Res 11: 99–104.

Sandberg, F., Dutschewska, H., Christov, V., Spassov, S., 1987. Spondianthus preussii

var. glaber Engler: Pharmacological screening and occurrence of triterpenes.

Acta Pharm Suec 24: 253–256.

Sanjivanjit, B., Karim, K., Ian, P., Greg, P., 2007. Mol. Pharmaceutics 4 (4): 556–560.

Sargent, J.M., 2003. The use of the MTT assay to study drug resistance in fresh tumour

samples. Recent Results Cancer Res 161:13-25.

http://pubs.acs.org/action/doSearch?action=search&author=Bhal%2C+Sanjivanjit+K.&qsSearchArea=authorhttp://pubs.acs.org/action/doSearch?action=search&author=Kassam%2C+Karim&qsSearchArea=authorhttp://pubs.acs.org/action/doSearch?action=search&author=Peirson%2C+Ian+G.&qsSearchArea=authorhttp://pubs.acs.org/action/doSearch?action=search&author=Pearl%2C+Greg+M.&qsSearchArea=authorhttp://www.ncbi.nlm.nih.gov/pubmed?term=Sargent%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=12528795http://www.ncbi.nlm.nih.gov/pubmed/12528795


305

Schmidt, D., Lynch, J., 2003. Evaluation of the reproducibility of Parallel Artificial

Membrane Permeability Assay (PAMPA). Millipore corporation application

note, Literature Notes AN1728EN00.

Schmidt, M.L., Kuzmanoff, K.L., Ling-Indeck, L., Pezzuto, J.M., 1997. Betulinic acid

induces apoptosis in human neuroblastoma cell lines. Eur J Cancer 33: 2007–

2010.

Schoene, C., Nedderman, A.N.R., Houghton, E., 1994. Preliminary study of the

metabolism of 17cx-methyltestosterone in horses utilizing gas chromatography-

mass spectrometric techniques. Analyst 119: 2537.

Seifert, M., Brenne-weib, G., Haindl, S., Nusser, M., Obst, U., Hock, B., 1999.

Frensenius. A new concept for the bioeffects-related analysis of xenoestrogens:

Hyphenation of receptor assays with LC-MS. J Anal Chern 363: 767.

Selby, P., Buick, R.N., Tannock I., 1983. A critical appraisal of the human tumor stem

cell assay. New England Journal of Medicine 308: 129-134.

Selick, H.E., Beresford, A.P., Tarbit, M.H., 2002.The emerging importance of predictive

ADME simulation in drug discovery. Drug Discov Today 7(2):109-16.

Selzer, E., Pimentel, E., Wacheck, V., Schlegel, W., Pehamberger, H., Jansen, B.,

Kodym, R., 2000. Effects of betulinic acid alone and in combination with

irradiation in human melanoma cells. J Invest Dermatol 114: 935– 940.

Seydel, J.K., Miller, G., Doukas, P.H. 1973. Structure-activity correlations of

sulfonamides in cell-free systems compared to correlations obtained in whole

cell systems and in vivo. in Medicinal Chemistry, ed Pratesi, P., (Butterworths,

London, UK), 139–151.

Seydel, J.K., Schaper, K.J., 1986. Quantitative structure-pharmacokinetic relationships

and drug design. in Pharmacokinetics: Theory and Methodology, eds Rowland,

M., Tucker, G., (Pergamon Press, New York), 311–366.

Shackleton, C.H.L., 1986. Profiling steroid hormones and urinary steroids. J Chromatogr

B. Biomed Appl 379: 91-156.

Shackleton, C.H.L., 1993.Mass spectrometry in the diagnosis of steroid-related disorders

and in hypertension research. J Steroid Biochem Molec Biol 45: 127-140.

Shah, V.P., Midha, K.K., Dighe, S., McGilveray, I.I., Skelly, J.P., Yacobi, A., Layloff,

T., Viswanathan, C.T., Cook, C.E., McDowall, R.D., Pittman, K.A., Spector, S.,

1992. Analytical methods validation: bioavailability, bioequivalence and

http://www.ncbi.nlm.nih.gov/pubmed?term=Selick%20HE%5BAuthor%5D&cauthor=true&cauthor_uid=11790621http://www.ncbi.nlm.nih.gov/pubmed?term=Beresford%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=11790621http://www.ncbi.nlm.nih.gov/pubmed?term=Tarbit%20MH%5BAuthor%5D&cauthor=true&cauthor_uid=11790621http://www.ncbi.nlm.nih.gov/pubmed/11790621


306

pharmacokinetic studies. Conference report. Pharm Res 9: 588-592.

Shah, V.P., Midha, K.K., Findlay, J.W., Hill, H.M., Hulse, J.D., McGilveray, I.I.,

McKay, G., Miller, K.J., Patnaik, R.N., Powell, M.L., Tonelli, A.,

Viswanathan, C.T., Yacobi, A., 2000. Bioanalytical method validation--a

revisit with a decade of progress. Pharm Res 17: 1551-1557.

Shand, D.G., Rangro, R.E., Evans, G.H., 1972. The disposition of propranolol. IL

Hepatic elimination in the rat. Pharmacol 8: 344.

Shargel, L., Yu, A.B.C., 1985. Applied pharmacokinetics and Biopharmaceutics, 2nd

edition. Appleton-Century Crafts, Norwalk, CT. 197.

Shargel, L., Yu, A.B.C., 1993. Applied Biopharmaceutics and Pharmacokinetics.

Appleton & Lange: Norwalk, Connecticut.

Sharma, A., Jusko W.J., 1998. Characteristics of indirect pharmacodynamic models and

application to clinical drug responses. Br J Clin Pharmacol 45: 229-239.

Shin, Y.G., Cho, K.H., Chung, S.M., Graham, J., Gupta, T.K.D., Pezzuto, J.M., 1999.

Determination of betulinic acid in mouse blood, tumor, and tissue homogenates

by liquid chromatography–electrospray mass spectrometry. J Chromatogr B

732: 331–336.

Singh, S.K., Mehrotra, N., Sabarinath, S., Gupta, R.C., 2003. HPLC-UV method

development and validation for 16-dehydropregnenolone, a novel oral

hypolipidaemic agent, in rat biological matrices for application to

phannacokinetic studies. J Pharm Biomed Anal 33: 755-764.

Singh, S.S., 2006 Preclinical pharmacokinetics: an approach towards safer and efficacious

drugs. Curr Drug Metab 7(2): 165-82.

Singh, S.S., Patro, B., Tripathi, V., Srivastava, A., Pandey, S.C., Ghosh, A.C., 2002.

Betulinic acid and its pharmacological activity-a review. J Med Aromatic Plant

Sci 24: 1031-1037.

Sippel, J., Suchy, F.J., Ananthanarayanan, M., Perlmutter, D.H., 1993. The rat liver

ectoATPase is also a canalicular bile acid transport protein. J Biol Chem 268:

2083-2091.

Smith, D.A., Obach, R.S., 2005. Drug Metab Dispos 33: 1409–1417.

Smith, R.L., 1973. The Excretory Function of Bile. The Elimination of Drugs and Toxic

Substances in Bile. Chapman and Hall, London.

http://www.ncbi.nlm.nih.gov/pubmed?term=Singh%20SS%5BAuthor%5D&cauthor=true&cauthor_uid=16472106http://www.ncbi.nlm.nih.gov/pubmed/16472106


307

Son, L.B., Kaplun, A.P., Symon, A.V., Shpilevsky, A.A., Grigoriev, V.B., Shvets, V.I.,

1998. Solubilization of betulinic acid, a new antimelanoma compound. Proceed

Int Symp Control Rel Bioact Mater 25: 419–420.

Sorokina, I.V., Tolstikova, T.G., Zhukova, N.A., Petrenko, N.I., Uzenkova, N.V.,

Shul’ts, E.E., Popova, N.A., 2006. Antitumor and Antimetastatic Effects of

Betulonic Acid Amides in Mice with Transplantable Lewis Carcinoma,

Bulletin of Experimental Biology and Medicine 142(1): 78-81.

Steele, J.C., Warhurst, D.C., Kirby, G.C., Simmonds, M.S., 1999. In vitro and in vivo

evaluation of betulinic acid as an antimalarial. Phytother Res 13: 115-119.

Stewart, B.H., Chan, O.H., Lu, R.H., Reyner, E.L., Schmid, H.L., Hamilton, H.W.,

Steinbaugh, B.A., Taylor, M.D., 1995. Comparison of intestinal permeabilities

determined in multiple in vitro and in situ models: relationship to absorption in

humans. Pharm Res 12: 693-699.

Stewart, B.W., Kleihues, P., 2003. ―WORLD CANCER REPORT‖ and Published by

International Agency for Research on Cancer, World Health Organization 12-

20.

Stewart, T.A., Pattengale, P.K., Leder, P., 1984. Spontaneous mammary adenocarcinomas

in transgenic mice that carry and express MTV/myc fusion genes. Cell 38: 627–

37.

Stoner, C.L., Gifford, E., Stankovic, C., Lepsy, C.S., Brodfuehrer, J., Prasad, J.V.,

Surendran, N., 2004. Implementation of an ADME enabling selection and

visualization tool for drug discovery. J Pharm Sci 93(5): 1131-41.

Subramanian, G., Mjalli, A.M., Kutz, M.E., 2006. Integrated approaches to perform in

silico drug discovery. Curr Drug Discov Technol 3(3): 189-97.

Sugawara, M., 2005. The use of an in vitro dissolution and absorption system to evaluate

oral absorption of two weak bases in pH-independent controlledrelease

formulations. Eur J Pharm Sci 26: 1–8.

Suggitt, M., Swaine, D.J., Pettit, G.R., Bibby, M.C., 2004. Characterisation of the hollow

fibre assay for the determination of microtubule disruption in vivo. Clin Cancer

Res 10: 6677–85.

http://www.ncbi.nlm.nih.gov/pubmed?term=Stoner%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Gifford%20E%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Stankovic%20C%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Lepsy%20CS%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Brodfuehrer%20J%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Prasad%20JV%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Surendran%20N%5BAuthor%5D&cauthor=true&cauthor_uid=15067690http://www.ncbi.nlm.nih.gov/pubmed/15067690http://www.ncbi.nlm.nih.gov/pubmed?term=Subramanian%20G%5BAuthor%5D&cauthor=true&cauthor_uid=17311564http://www.ncbi.nlm.nih.gov/pubmed?term=Mjalli%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=17311564http://www.ncbi.nlm.nih.gov/pubmed?term=Kutz%20ME%5BAuthor%5D&cauthor=true&cauthor_uid=17311564http://www.ncbi.nlm.nih.gov/pubmed/17311564


308

Sun, D., Yu, L.X., Hussain, M.A., Wall, D.A., Smith, R.L., Amidon, G.L., 2004 . In vitro

testing of drug absorption for drug developability assessment: forming an

interface between in vitro preclinical data and clinical outcome. Curr Opin Drug

Discov Devel 7(1): 75.

Suto, A., Kubota, T., Shimoyama, Y., Ishibiki, K., Abe, O., 1989. MTT assay with

reference to the clinical effect of chemotherapy. J Surg Oncol 42: 28-32.

Symon, A.V., Veselova, N.N., Kaplun, A.P., Vlasenkova, N.K., Fedorova, G.A.,

Lyutik, A.I., Gerasimov, G.K., Shvets, V.I., 2005. Synthesis and Antitumor

Activity of Cyclopropane Derivatives of Betulinic and Betulonic Acids,

Russian Journal of Bioorganic Chemistry 31(3): 286–291.

Syrovets, T., Buchele, B., Gedig, E., Slupsky, J.R., Simmet, T., 2000. Acetyl-boswellic

acids are novel catalytic inhibitors of human topoisomerase I and IIa. Mol

Pharm 58: 71–81.

Tarbit, M.H., Berman, J., 1998. High throughput approach for evaluating absorption,

distribution, metabolism and excretion properties of lead compounds. Cur Opin

Chem Biol 2: 411-416.

Tassaneeyakul, W., Birkett, D.J., Veronese, M.E., McManus, M.E., Tukey, R.H.,

Quattrochi, L.C., Gelboin, H.V., Miners, J.O., 1993. Specificity of substrate and

inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp

Ther 265(1): 401-7.

Thomas, O., Greg, K., MultiScreen® Solubility Filter Plate. Quantitative method to

determine drug aqueous solubility: optimization and correlation to standard

method.

Thompson, T.N., 2000. Early ADME in support of drug discovery : the role of metabolic

stability studies . Curr Drug Metab 1(3): 215.

Toon, S., Rowland, M., 1983. Structure-pharmacokinetic relationships among the

barbiturates in the rat. J Pharmacol Exp Ther 225: 752–763.

Twentyman, P.R., Fox, N.E., Rees, J.K.H., 1989. Chemosensitivity testing of fresh

leukaemia cells using the MTT colorimetric assay. Br J Haematol 71: 19-24.


309

U.S. Environmental Protection Agency, 1997. Health Effects Test Guidelines OPPTS

870.7485 Metabolismand Pharmacokinetics.

www.epa.gov/epahome/research.htm

U.S. FDA, Guidance for Industry. Estimating the maximum safe starting dose in initial

clinical trials for therapeutics in adult healthy volunteers. 2005.


U.S. FDA., 1997. Guidance for Industry. Drug metabolism/drug interaction studies in the

drug development process: studies in vitro. www.fda.gov/cder/guidance

U.S. FDA., 2002. Guideline for Metabolism Studies and for Selection of Residues for

Toxicological Testing. www.fda.gov/cvm/guidance/guideline3pt1.html

U.S. FDA., 2005. Guidance for Industry. Safety Testing of Drug Metabolites.


Udeani, G.O., Zhao, G.M., Shin, Y.G., Cooke, B.P., Graham, J., Beecher, C.W.W.,

Kinghorn, A.D., Pezzuto, J.M., 1999. Pharmacokinetics and tissue distribution

of betulinic acid in CD-1 mice. Biopharm Drug Dispos 20: 379–383.

Ungell, A.B., 2004. Caco-2 replace or refine?. Drug Discov Today Technol 1(4): 423-430.

Ungell, A-L. 1997. In vitro absorption studies and their relevance to absorption from the

GI tract. Drug Dev Industr Pharm 23: 879-892.

Unger, S.E., 1999. Using mass spectrometry to determine ADME properties III drug

discovery. Annu Rep Med Chern 34: 307-316.

Urban, M., Sarek, J., Klinot, J., Korinkova, G., Hajduch, M., 2004. Synthesis of A-seco

derivatives of betulinic acid with cytotoxic activity. J Nat Prod 67: 1100-1105.

Valner, J.J., 1977. Binding of drugs with albumin and plasma proteins. J Pharm Sci 66:

447.

Van, W.H., 2002. High-throughput and in silico techniques in drug metabolism and

pharmacokinetics, Curr Opin Drug Discov Devel 5(1): 33-43.

Van, W.H., 2005. From in vivo to in vitro/in silico ADME: progress and challenges.

Expert Opin Drug Metab Toxicol 1(1):1-4.

Van, W.H., Gifford, E., 2003. ADMET in silico modelling: towards prediction paradise?

Nat Rev Drug Discov 2(3):192-204.

Van-Hoof, N., Courtheyn, D., Philippe-Antignac, J., Van-De-Wiele, M., Poelmans, S.,

Noppe, H., Brabander, D., 2005. Multi-residue liquid chromatography/tandem

http://www.epa.gov/epahome/research.htmhttp://www.fda.gov/cder/guidancehttp://www.fda.gov/cder/guidancehttp://www.ncbi.nlm.nih.gov/pubmed?term=van%20de%20Waterbeemd%20H%5BAuthor%5D&cauthor=true&cauthor_uid=11865671http://www.ncbi.nlm.nih.gov/pubmed/11865671http://www.ncbi.nlm.nih.gov/pubmed/16922647http://www.ncbi.nlm.nih.gov/pubmed?term=van%20de%20Waterbeemd%20H%5BAuthor%5D&cauthor=true&cauthor_uid=12612645http://www.ncbi.nlm.nih.gov/pubmed?term=Gifford%20E%5BAuthor%5D&cauthor=true&cauthor_uid=12612645htt

8. bibliography - shodhgangashodhganga.inflibnet.ac.in/bitstream/10603/25882/14/part... · 2018. 7....

Documents